Table 5. Longitudinal DTI assessment of Alzheimer's disease in the splenium.

Splenium			Longitudinal
	Baseline (N = 16) vs.Control (N = 26)	12 months (N = 16) vs.Control (N = 26)	12 months (N = 16) vs.Baseline (N = 16)
λ1	2.37§	1.54	−0.52
RD	1.72	2.97**	−2.59*
MD	2.47§	2.71*	−1.76
FA	−0.87	−2.58*	−2.64*

Baseline and 12 months versus controls comparisons are reported as Wilcoxon rank-sum Z-statistic values; paired longitudinal results are given as Wilcoxon signed-rank Z-statistic.

Significance levels: ^§0.01<P<0.05 (Alzheimer’s disease worse than controls, two-tailed); *P<0.01 (Alzheimer’s disease worse than controls; or 12 months worse than baseline, two-tailed); **P<0.05 (Alzheimer’s disease worse than controls, two-tailed, Bonferroni-corrected on n = 12).